UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | September 11, 2007 |
Inhibitex, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 0-50772 | 742708737 |
| _____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 9005 Westside Parkway, Alpharetta, Georgia | 30004 | |
| _________________________________ (Address of principal executive offices) | ___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 678-746-1100 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[x] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On September 11, 2007, the Company entered into an exclusive worldwide license agreement with the University of Georgia Research Foundation (UGARF) for intellectual property covering a series of HIV integrase inhibitors in exchange for an upfront license fee of approximately $750,000 in cash and approximately 226,000 shares of the Company’s common stock, future milestone payments and royalties on future net sales. The license agreement also includes intellectual property related to a series of HCV polymerase inhibitors. In addition, Inhibitex entered into a sponsored research agreement with UGARF to provide up to three years of financial support for specified research and development activities to be performed at the University of Georgia related to the licensed programs.
Item 8.01 Other Events.
On September 11, 2007, Inhibitex, Inc. issued a press release announcing a license agreement with the University of Georgia Research Foundation. A copy of the press release is furnished as Exhibit 99.1 to this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description of Exhibits
________________________________________
99.1 Press Release dated September 11, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Inhibitex, Inc. | ||||
| September 11, 2007 | By: | Russell H. Plumb | ||
| Name: Russell H. Plumb | ||||
| Title: Chief Executive Officer | ||||
Exhibit Index
| Exhibit No. | Description | |
99.1 | Press Release dated September 11, 2007. |
